Louisiana Pain Specialists, Llc

CLIA Laboratory Citation Details

3
Total Citations
30
Total Deficiencyies
25
Unique D-Tags
CMS Certification Number 19D2124201
Address 2706 Hessmer Ave, Suite A, Metairie, LA, 70002
City Metairie
State LA
Zip Code70002
Phone504 754-2334
Lab DirectorDAVID GREEN

Citation History (3 surveys)

Survey - April 28, 2025

Survey Type: Standard

Survey Event ID: UE6K11

Deficiency Tags: D0000 D5413 D5805 D6087 D6098 D6098 D6112 D6112

Summary:

Summary Statement of Deficiencies D0000 A Recertification survey was performed at Louisiana Pain Specialists, LLC, CLIA ID 19D2124201, on April 28, 2025. The laboratory was found in compliance with 42 CFR 493 Requirements for Laboratories; however, standard level deficiencies were cited. D5413 TEST SYSTEMS, EQUIPMENT, INSTRUMENTS, REAGENT CFR(s): 493.1252(b) (b) The laboratory must define criteria for those conditions that are essential for proper storage of reagents and specimens, accurate and reliable test system operation, and test result reporting. The criteria must be consistent with the manufacturer's instructions, if provided. These conditions must be monitored and documented and, if applicable, include the following: (b)(1) Water quality. (b)(2) Temperature. (b)(3) Humidity. (b)(4) Protection of equipment and instruments from fluctuations and interruptions in electrical current that adversely affect patient test results and test reports. This STANDARD is not met as evidenced by: Based on observation by surveyor, review of manufacturer's Certificate of Analysis documents, and interview with personnel, the laboratory failed to ensure two (2) of thirty-six (36) Cerilliant standards for Toxicology testing were stored per the manufacturer's requirements. Findings: 1. Observation by surveyor during the laboratory tour on April 28, 2025 at 9:38 am revealed the following Cerilliant standards stored in the "LC-MS" reagent freezer: a) Cerilliant Morphine-3-B-D- glucuronide: lot FE11142310, quantity: one (1) vial and lot FE07262109, quantity: one (1) vial. The manufacturer's label stated "Refrigerate (Do Not Freeze)." b) Cerilliant 6-Acetylmorphine: lot FE07082101, quantity: one (1) vial. The manufacturer's label stated "Refrigerate." 2. Review of the manufacturer's Certificate of Analysis sheets revealed the following storage requirements: a) Cerilliant Morphine-3-B-D-glucuronide: "Store unopened and upright in refrigerator (2 degrees Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 3 -- Celsius (C) to 8 degrees C) b) Cerilliant 6-Acetylmorphine: "Store unopened and upright in refrigerator (2 degrees C to 8 degrees C) 3. In interview on April 28, 2025 at 9:50 am, the Technical Supervisor confirmed the two (2) identified Cerilliant standards were not stored in a refrigerator per the manufacturer's requirments. D5805 TEST REPORT CFR(s): 493.1291(c) (c) The test report must indicate the following: (c)(1) For positive patient identification, either the patient's name and identification number, or a unique patient identifier and identification number. (c)(2) The name and address of the laboratory location where the test was performed. (c)(3) The test report date. (c)(4) The test performed. (c)(5) Specimen source, when appropriate. (c)(6) The test result and, if applicable, the units of measurement or interpretation, or both. (c)(7) Any information regarding the condition and disposition of specimens that do not meet the laboratory's criteria for acceptability. This STANDARD is not met as evidenced by: Based on review of the laboratory's CLIA certificate, patient final test reports, test menu, and interview with personnel, the laboratory failed to utilize the correct CLIA identification number of the testing laboratory for seven (7) of seven (7) patient Toxicology reports reviewed. Findings: 1. Review of the laboratory's CLIA certificate revealed the CLIA identification number as 19D2124201. 2. Review of random selection of patient final test reports for Toxicology revealed the laboratory provided the CLIA identification number, 19D2119690, of a closed laboratory for the following patients: Patient LA255134A Patient LA256069A Patient LA255147A Patient LA254041A Patient LA253063A Patient LD243131A Patient LH244203A 3. In interview on April 28, 2025 at 12:35 pm, the Technical Supervisor stated the CLIA listed on the patient final reports was incorrect. 4. Review of the laboratory's test menu revealed the laboratory performs 251,700 Toxicology tests annually. D6087 LABORATORY DIRECTOR RESPONSIBILITIES CFR(s): 493.1445(e)(3)(iii) (e)(3)(iii) Laboratory personnel are performing the test methods as required for accurate and reliable results; This STANDARD is not met as evidenced by: Based on observation by surveyor, record review, and interview with personnel, the Laboratory Director failed to ensure the laboratory personnel performed test methods as required. Refer to D5413. D6098 LABORATORY DIRECTOR RESPONSIBILITIES CFR(s): 493.1445(e)(8) (e)(8) Ensure that reports of test results include pertinent information required for interpretation; This STANDARD is not met as evidenced by: Based on record review and interview with personnel, the Laboratory Director failed -- 2 of 3 -- to ensure patient final reports included required pertinent information. Refer to D5805. D6112 TECHNICAL SUPERVISOR RESPONSIBILITIES CFR(s): 493.1451 The technical supervisor is responsible for the technical and scientific oversight of the laboratory. The technical supervisor is not required to be on site at all times testing is performed; however, he or she must be available to the laboratory on an as needed basis to provide supervision as specified in (a) of this section. This STANDARD is not met as evidenced by: Based on observation by surveyor, record review, and interview with personnel, the Technical Supervisor failed to provide technical and scientific oversight for the laboratory. Findings: 1. The laboratory failed to ensure two (2) of thirty-six (36) Cerilliant standards for Toxicology testing were stored per the manufacturer's requirements. Refer to D5413. 2. The laboratory failed to utilize the correct CLIA identification number of the testing laboratory for seven (7) of seven (7) patient Toxicology reports reviewed. Refer to D5805. -- 3 of 3 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access

Survey - August 22, 2023

Survey Type: Standard

Survey Event ID: CY9Y11

Deficiency Tags: D5403 D6092 D6112 D0000 D5217 D5221 D6087 D6106

Summary:

Summary Statement of Deficiencies D0000 A Certification survey was performed at Louisiana Pain Specialists, LLC, CLIA ID # 19D2124201, on August 22, 2023. The laboratory was found in compliance with 42 CFR 493 Requirements for Laboratories; however, standard deficiencies were cited. D5217 EVALUATION OF PROFICIENCY TESTING PERFORMANCE CFR(s): 493.1236(c)(1) At least twice annually, the laboratory must verify the accuracy of any test or procedure it performs that is not included in subpart I of this part. This STANDARD is not met as evidenced by: Based on review of the laboratory's policies, records, test menu, and interview with personnel, the laboratory failed to verify the accuracy of Urine Drug Confirmation testing in 2023 at least one (1) out of two (2) times annually as required. Findings: 1. Review of the laboratory's "Proficiency Testing" policy revealed "For Alternative PT surveys: Must take place at least twice per year, approximately 6 months apart." 2. Review of the laboratory's test menu, proficiency testing and alternative proficiency testing records from April 2023 revealed the laboratory did not have documentation of alternative proficiency testing that covered the following drugs for the first half (January through June) of 2023: 6-MAM, 7-Aminoclonazepam, Alpha- hydroxyalprazolam, Alprazolam, Amphetamine, Benzoylecgonine, Carisoprodol, Clonazepam, Coedine, Diazepam, EDDP, Ketamine, MDMA, Meperidine, Meprobmate, Methamphetamine, Morphine, Nordiazepam, Normeperidine, Noroxycodone, Oxazepam, Oxycodone, Oxymorphone, PCP, Tapentadol, and Temazepam. 3. In interview on August 22, 2023 at 3:33 pm, the Technical Supervisor confirmed the laboratory did not verify the accuracy of Urine Drug Confirmation testing for the identified drugs for the first half of 2023. D5221 EVALUATION OF PROFICIENCY TESTING PERFORMANCE CFR(s): 493.1236(d) Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 3 -- All proficiency testing evaluation and verification activities must be documented. This STANDARD is not met as evidenced by: Based on review of the laboratory's policies, proficiency testing (PT) records, and interview with personnel, the laboratory failed to have documentation of the Laboratory Director's review of unacceptable results for Urine Drug Confirmation testing for one (1) of two (2) events in 2022. Findings: 1. Review of the laboratory's "Proficiency Testing" policy under the "Review of

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access

Survey - January 9, 2018

Survey Type: Standard

Survey Event ID: IV5012

Deficiency Tags: D5209 D5435 D6086 D6108 D6115 D6143 D6170 D5022 D5423 D6076 D6102 D6111 D6141 D6168

Summary:

Summary Statement of Deficiencies No Tags No deficiency details available. Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 1 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access